Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-09EMA Authorised: Harvoni (ledipasvir;sofosbuvir) — Gilead Sciences Ireland UC
The EMA authorised Harvoni (ledipasvir and sofosbuvir) for chronic hepatitis C, with decision dated 12 January 2023.
-
EMA approval · 2026-01-09EMA Authorised: Sovaldi (sofosbuvir) — Gilead Sciences Ireland UC
The European Medicines Agency authorised Sovaldi (sofosbuvir) for chronic hepatitis C, with accelerated assessment noted in the decision. Th…
-
EMA approval · 2025-11-20EMA Authorised: Maviret (glecaprevir;pibrentasvir) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Maviret (glecaprevir/pibrentasvir) for chronic hepatitis C, with AbbVie Deutschland GmbH & Co. KG a…
-
EMA approval · 2025-11-07EMA Authorised: Zepatier (elbasvir;grazoprevir) — Merck Sharp & Dohme B.V.
The EMA has authorised Zepatier (elbasvir/grazoprevir) for chronic hepatitis C infection with Merck Sharp & Dohme B.V. as the marketing auth…
-
EMA approval · 2025-11-05EMA Authorised: Pegasys (peginterferon alfa-2a) — pharmaand GmbH
EMA authorised Pegasys (peginterferon alfa-2a) for chronic hepatitis C, chronic hepatitis B, polycythemia vera, and essential thrombocythemi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-06-10FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) from AbbVie Inc., updating the regulatory status of t…
-
FDA approval · 2025-06-10FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) submitted by AbbVie.
-
FDA approval · 2025-04-15FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) submitted by AbbVie.
-
FDA approval · 2024-12-23FDA Approved: SOVALDI — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for Sovaldi (sofosbuvir) submitted by Gilead Sciences, Inc. The approval expands the approved use of…
-
FDA approval · 2024-12-19FDA Approved: HARVONI — Supplemental Application (Gilead Sciences, Inc)
FDA approved a supplemental application for HARVONI (ledipasvir and sofosbuvir) to modify labeling and/or expand its indications.
-
FDA approval · 2024-12-19FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)
The FDA approved a supplemental application for ledipasvir and sofosbuvir submitted by Asegua Therapeutics LLC.
-
FDA approval · 2023-10-25FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
FDA document regarding a supplemental application for MAVYRET (glecaprevir and pibrentasvir) by AbbVie.
-
FDA approval · 2023-10-25FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) from AbbVie.
-
EMA approval · 2023-09-27EMA Authorised: Epclusa (sofosbuvir;velpatasvir) — Gilead Sciences Ireland UC
EPAR entry indicating EMA authorised Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C, with Gilead as MAH and accelerated assessment…
-
EMA approval · 2023-09-27EMA Authorised: Vosevi (sofosbuvir;velpatasvir;voxilaprevi) — Gilead Sciences Ireland UC
EMA authorised Vosevi (sofosbuvir; velpatasvir; voxilaprevir) for chronic hepatitis C.
-
FDA approval · 2022-12-14FDA Approved: EPCLUSA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for Epclusa (velpatasvir/sofosbuvir) from Gilead Sciences.
-
FDA approval · 2022-04-27FDA Approved: EPCLUSA — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for Epclusa (velpatasvir/sofosbuvir) from Gilead Sciences, which expands the established use of the …
-
FDA approval · 2022-04-27FDA Approved: EPCLUSA — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for Epclusa (velpatasvir and sofosbuvir) by Gilead Sciences, Inc.
-
FDA approval · 2021-12-09FDA Approved: ZEPATIER — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for ZEPATIER (elbasvir and grazoprevir) from Merck Sharp & Dohme LLC.
-
FDA approval · 2021-09-28FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) from AbbVie.
-
FDA approval · 2021-09-28FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) submitted by AbbVie.
-
FDA approval · 2021-06-10FDA Approved: MAVYRET — Original Application (AbbVie Inc.)
FDA approved MAVYRET (glecaprevir and pibrentasvir) from AbbVie in its original application for the treatment of hepatitis C virus infection…
-
FDA approval · 2021-06-10FDA Approved: EPCLUSA — Original Application (Gilead Sciences, Inc.)
FDA approved Epclusa (velpatasvir/sofosbuvir) in an original application for the treatment of chronic hepatitis C virus infection.
-
FDA approval · 2021-06-10FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) submitted by AbbVie, potentially updating its labelin…
-
FDA approval · 2021-06-10FDA Approved: EPCLUSA — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for EPCLUSA (velpatasvir/sofosbuvir) from Gilead Sciences, Inc.